NOV 12, 2020 6:00 AM PST

Standardization with Clinical Digital Pathology - The Ki-67 Case

Sponsored by: Visiopharm®
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Clinical Development Engineer, Data Lead
    Biography

      Dzenita is a Clinical Development Engineer at Visiopharm. She holds a M.Sc. in Biomedical Engineering with a focus on medical image analysis from the Technical University of Denmark. Over the last 5 years, she has been involved in the development of CE-IVD APPs for the Visiopharm software platform, including data sourcing and management, and she specializes in external collaborations and projects with a clinical/CE-IVD/FDA scope.


    Abstract

    The nuclear proliferation biomarker Ki-67 has multiple potential roles in breast and other cancers, both as a prognostic but also predictive marker. However, several studies have shown that the assessment of Ki-67 with immunohistochemistry (IHC) suffers from both intra-and inter-observer variability and low reproducibility. On top of that it is still being debated what the most appropriate way of scoring Ki-67 IHC is - should one use global scoring or the hot spot scoring method? In this webinar we will look into how Visiopharm CE-IVD APPs can be used for standardizing the assessment of Ki-67 IHC. We will also show how the APPs can accommodate both the global scoring method and the hot spot scoring method allowing for a tailored solution that fits the diagnostic workflow in your laboratory. We will focus on the clinically validated APPs, but will also reveal some of the AI technologies we have for research use.

    Learning Objectives:

    1. Understand the limitations of manual biomarker assessment in image analysis

    2. Learn how CE-IVD APPs can used for standardization of Ki-67 scoring

    3. Get a glimpse of the future AI-powered workflows for biomarker analysis


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    APR 20, 2021 11:00 AM PDT
    C.E. CREDITS
    APR 20, 2021 11:00 AM PDT
    Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
    Loading Comments...
    Show Resources